Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04383457
Other study ID # U1111-1251-4114
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 15, 2020
Est. completion date October 8, 2020

Study information

Verified date November 2020
Source Vastra Gotaland Region
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The vital signs are critical in assessing the severity and prognosis of infections, such as Covid-19. The devices used today for measuring the vital signs have to be in physical contact with the patients. There is an apparent risk of transferring infections from one patient to the next (or to healthcare professionals). This project aims to evaluate a new camera-based system for contactless measurement of vital signs as well as an artificial intelligence (AI) predicting hospitalization or death within 30 days. This particular study will evaluate the new system's ability without interfering with standard care of the patient.


Description:

Background and aim: The vital signs are critical in assessing the severity and prognosis of infections, i.e., Covid-19, influenza, sepsis and pneumonia. Quick and accurate triage is critical when facing a pandemic with an overwhelming number of cases (confirmed and suspected). This study aims a) to evaluate a new method for rapid camera-based non-contact measurement of five vital signs; body temperature, heart rate, blood oxygen saturation, respiratory rate, and blood pressure, and b) if an AI can predict hospitalization or death within 30 days. Methods: A method-comparison study design is used comparing each vital sign measured with the new method to the corresponding standard reference method. Furthermore, a cohort design is used to follow up any hospitalization or death within 30 days. The investigated new system consists of a high-speed digital video camera, a digital radiometric infrared camera, LED lights and a computer for data recording. This system faces the subject at a distance of approximately one meter, capturing a 30 second recording of the subject's face. First, all vital signs will be measured using one set of reference devices. Secondly the investigated device will record a 30 second video of the patient's face. Thirdly, and last, all vital signs will be measured using the same set of reference devices. A copy of the vital sign readings (using the standard reference methods) will be handed over by an investigator to the clinical professionals responsible for the subsequent medical care for each subject. Afterwards, the collected 30-second recordings will be run through specific software algorithms to extract the vital signs. The results from the new camera-based contactless measurement of vital signs and the outcome of the AIs prediction of risk for hospitalization or death will not be presented in the care situation of the patient. Expected Findings: It is expected that the proposed study will show that the new method can estimate body temperature, heart rate, respiratory rate, blood oxygen level, and blood pressure with an acceptable agreement compared with the reference method and also estimate hospitalization or death within 30 days. Implications of the expected findings: Being able to measure vital signs quicker than before by using a new contactless method would greatly facilitate triage of large number of patients. Also being able to predict hospitalization or increased risk for death would further improve the triage of patients.


Recruitment information / eligibility

Status Completed
Enrollment 214
Est. completion date October 8, 2020
Est. primary completion date October 8, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. The patient is attending for triage presenting with symptoms of an infection. 2. Subject has provided informed consent 3. Age =18 years 4. Fluent in Swedish (reading, writing, conversational) 5. Mental state is such that he or she is able to understand and give informed consent to participation in the study by signing the Information and Consent Form 6. The investigator determines that the new method, and the reference methods, can be used as intended with adequate reliability and safety 7. The time for investigations in this study is estimated to approximately 15-20 minutes. Vital signs will be handed over to the care provider responsible for the further management of the patient saving approximately 5-10 minutes of their time. Hence, the delay in the management of each patient introduced by this study is approximately 10 minutes. Patients deemed being in such a severe medical condition on arrival, that 10 minutes of delay is deemed detrimental will not be included. Exclusion Criteria: 1. Depressed level of consciousness from inclusion up until all investigations are completed (during approximately 15-20 minutes). 2. Patient request to be withdrawn from the study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
RIA-device (Remote Investigation and Assessment)
The investigated new system consists of a high-speed digital video camera, a digital radiometric infrared camera, LED lights and a computer for data recording. This system faces the subject at a distance of approximately one meter, capturing a 30 second recording of the subject's face.

Locations

Country Name City State
Sweden Östra Sjukhuset Gothenburg

Sponsors (2)

Lead Sponsor Collaborator
Vastra Gotaland Region Detectivio AB

Country where clinical trial is conducted

Sweden, 

References & Publications (1)

Malmberg S, Khan T, Gunnarsson R, Jacobsson G, Sundvall PD. Remote investigation and assessment of vital signs (RIA-VS)-proof of concept for contactless estimation of blood pressure, pulse, respiratory rate, and oxygen saturation in patients with suspicio — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Agreement between the new camera based method and reference standard to estimate body temperature Body temperature will be measured with the new camera based method as well as with a conventional ear thermometer. Both measurements will estimate the body temperature in degrees Celsius. The agreement between body temperature estimated with the new method and the reference method will be made using the statistical methods Bland-Altman plots and limits of agreement as the outcome. Two minutes between measurements
Primary Agreement between the new camera based method and reference standard to estimate heart rate Heart rate will be measured with the new camera based method as well as with a conventional apparatus for measuring pulse rate. Both measurements will estimate the heart rate in beats per minute. The agreement between body temperature estimated with the new method and the reference method will be made using the statistical methods Bland-Altman plots and limits of agreement as the outcome. Two minutes between measurements
Primary Agreement between the new camera based method and reference standard to estimate blood oxygen saturation Blood oxygen saturation will be measured with the new camera based method as well as with a conventional apparatus for measuring blood oxygen saturation. Both measurements will estimate the blood oxygen saturation in percent (ranging from 0-100%). The agreement between blood oxygen saturation estimated with the new method and the reference method will be made using the statistical methods Bland-Altman plots and limits of agreement as the outcome. Two minutes between measurements
Primary Agreement between the new camera based method and reference standard to estimate systolic blood pressure Systolic blood pressure will be measured with the new camera based method as well as with a conventional apparatus for measuring systolic blood pressure. Both measurements will estimate the systolic blood pressure in mm Hg. The agreement between systolic blood pressure estimated with the new method and the reference method will be made using the statistical methods Bland-Altman plots and limits of agreement as the outcome. Two minutes between measurements
Primary Agreement between the new camera based method and reference standard to estimate diastolic blood pressure Diastolic blood pressure will be measured with the new camera based method as well as with a conventional apparatus for measuring diastolic blood pressure. Both measurements will estimate the diastolic blood pressure in mm Hg. The agreement between diastolic blood pressure estimated with the new method and the reference method will be made using the statistical methods Bland-Altman plots and limits of agreement as the outcome. Two minutes between measurements
Primary Agreement between the new camera based method and reference standard to estimate respiratory rate Respiratory rate will be measured with the new camera based method as well as manually using a stethoscope. Both measurements will estimate the respiratory rate in breath per minute. The agreement between respiratory rate estimated with the new method and the reference method will be made using the statistical methods Bland-Altman plots and limits of agreement as the outcome. Two minutes between measurements
Secondary Prediction of hospital admission using vital signs estimated using reference standard methods An artificial intelligence (AI) algorithm will use 75% of patient observations of vital signs for training and the remaining 25% will be used to test the AIs predictive capabilities to predict hospital admission within 30 days. For each patient the AI will produce a probability (0-100%) for hospital admission within 30 days. These probabilities will undergo a receiver operating (ROC) analysis where area under curve (AUC) with 95% confidence interval will be the reported outcome measure. Hospital admission for any cause up until 30 days after inclusion
Secondary Prediction of death using vital signs estimated using reference standard methods An artificial intelligence (AI) algorithm will use 75% of patient observations of vital signs for training and the remaining 25% will be used to test the AIs predictive capabilities to predict death within 30 days. For each patient the AI will produce a probability (0-100%) for death within 30 days. These probabilities will undergo a receiver operating (ROC) analysis where area under curve (AUC) with 95% confidence interval will be the reported outcome measure. Death for any cause up until 30 days after inclusion
Secondary Prediction of hospital admission using vital signs estimated using the new camera based method An artificial intelligence (AI) algorithm will use 75% of patient observations of vital signs for training and the remaining 25% will be used to test the AIs predictive capabilities to predict hospital admission within 30 days. For each patient the AI will produce a probability (0-100%) for hospital admission within 30 days. These probabilities will undergo a receiver operating (ROC) analysis where area under curve (AUC) with 95% confidence interval will be the reported outcome measure. Hospital admission for any cause up until 30 days after inclusion
Secondary Prediction of death using vital signs estimated using the new camera based method An artificial intelligence (AI) algorithm will use 75% of patient observations of vital signs for training and the remaining 25% will be used to test the AIs predictive capabilities to predict death within 30 days. For each patient the AI will produce a probability (0-100%) for hospitalization within 30 days. These probabilities will undergo a receiver operating (ROC) analysis where area under curve (AUC) with 95% confidence interval will be the reported outcome measure. Death for any cause up until 30 days after inclusion
Secondary Prediction of hospital admission using raw camera data An artificial intelligence (AI) algorithm will use 75% of patient observations of raw camera data for training and raw data from the remaining 25% of patients will be used to test the AIs predictive capabilities to predict hospital admission within 30 days. For each patient the AI will produce a probability (0-100%) for hospital admission within 30 days. These probabilities will undergo a receiver operating (ROC) analysis where area under curve (AUC) with 95% confidence interval will be the reported outcome measure. Hospital admission for any cause up until 30 days after inclusion
Secondary Prediction of death using raw camera data An artificial intelligence (AI) algorithm will use 75% of patient observations of raw camera data for training and raw data from the remaining 25% of patients will be used to test the AIs predictive capabilities to predict death within 30 days. For each patient the AI will produce a probability (0-100%) for death within 30 days. These probabilities will undergo a receiver operating (ROC) analysis where area under curve (AUC) with 95% confidence interval will be the reported outcome measure. Death for any cause up until 30 days after inclusion
See also
  Status Clinical Trial Phase
Completed NCT04553575 - CoViD-19 Patient in Reims University Hospital in March to April 2020
Active, not recruiting NCT05033847 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 2
Active, not recruiting NCT05548439 - Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a Phase 1
Completed NCT05046548 - This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 Phase 1/Phase 2
Active, not recruiting NCT05726084 - Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older Phase 2/Phase 3
Recruiting NCT05069129 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 1/Phase 2
Enrolling by invitation NCT05054075 - Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19 Phase 2
Recruiting NCT05599516 - Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial Phase 3
Completed NCT05047900 - The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community N/A
Completed NCT04420286 - Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France
Completed NCT04424355 - Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.
Completed NCT05083039 - Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Terminated NCT04409873 - Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) Phase 2
Enrolling by invitation NCT04327349 - Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial N/A
Completed NCT04321278 - Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II) Phase 3
Recruiting NCT04327570 - In-depth Immunological Investigation of COVID-19.
Completed NCT04326309 - Audio Data Collection for Identification and Classification of Coughing
Recruiting NCT04322344 - Escin in Patients With Covid-19 Infection Phase 2/Phase 3
Completed NCT04328129 - Household Transmission Investigation Study for COVID-19 in Tropical Regions N/A
Completed NCT04323592 - Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome